Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(145 products)
- Bcr-Abl(102 products)
- EGFR(572 products)
- FAK(72 products)
- FLT(92 products)
- Fibroblast Growth Factor Receptor (FGFR)(170 products)
- JAK(245 products)
- PDGFR(126 products)
- RAAS(86 products)
- Src(78 products)
- Syk(38 products)
- Thrombin(47 products)
- VDA(2 products)
- VEGFR(268 products)
Show 6 more subcategories
Found 1414 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
(R)-Afatinib
CAS:<p>(R)-Afatinib: oral ErbB inhibitor (EGFR/HER2), IC50 ≤14 nM. For ESCC, NSCLC, gastric cancer research.</p>Formula:C24H25ClFN5O3Color and Shape:SolidMolecular weight:485.94MAX-40279 hemiadipate
CAS:<p>MAX-40279 hemiadipate: Potent FLT3/FGFR inhibitor; potential in AML treatment. (Patent WO2021180032A1)</p>Formula:C50H56F2N12O6S2Color and Shape:SolidMolecular weight:1023.19TX-1123
CAS:<p>TX-1123: PTK/COX inhibitor, Src/eEF2-K/PKA/EGFR-K/PKC targeted, IC50 of 1.16μM(COX2), 15.7μM(COX1), low mitochondrial toxicity.</p>Formula:C20H24O3Color and Shape:SolidMolecular weight:312.4NSC-689857
CAS:<p>NSC-689857 is an inhibitor that acts in the Skp2-Cks1 protein-protein interaction and p27Kip1 ubiquitination in vitro.</p>Formula:C25H29NO4Purity:98%Color and Shape:SolidMolecular weight:407.5EGFR/HER2/CDK9-IN-2
CAS:<p>EGFR/HER2/CDK9-IN-2 inhibits EGFR, HER2, CDK9 with IC50s: 145.35, 129.07, 117.13 nM; strong antitumor effects.</p>Formula:C23H20N4O5S2Color and Shape:SolidMolecular weight:496.56GDC-0834 Racemate
CAS:<p>GDC-0834 Racemate is the racemate form of GDC-0834, which is an effective and selective BTK inhibitor</p>Formula:C33H36N6O3SColor and Shape:SolidMolecular weight:596.74OD36
CAS:<p>OD36: Potent RIPK2 inhibitor, IC50=5.3 nM; hinders ALK2 signaling and osteogenesis, KD=37 nM; targets ALK2 ATP pocket.</p>Formula:C16H15ClN4O2Purity:99.89%Color and Shape:SolidMolecular weight:330.77GW768505A free base
CAS:<p>GW768505A free base is a potent dual inhibitor of VEGFR2 (KDR) and Tie-2 (pIC50: 7.81 for VEGFR2) with anti-angiogenic activity.</p>Formula:C27H19F4N5O3Color and Shape:SolidMolecular weight:537.47JAK3/BTK-IN-5
CAS:<p>JAK3/BTK-IN-5 is a potent dual inhibitor targeting JAK3 and BTK with synergistic effects, valuable for related autoimmune disease research.</p>Formula:C19H22ClN7O2Color and Shape:SolidMolecular weight:415.88T-1840383
CAS:<p>T-1840383 blocks VEGFR-2 and c-Met phosphorylation in endothelial and cancer cells.</p>Formula:C30H25ClFN5O4Color and Shape:SolidMolecular weight:574PD 166326
CAS:<p>PD166326, a pyridopyrimidine inhibitor, targets Src & Abl tyrosine kinases (IC50: 6 nM & 8 nM) and exhibits antileukemic effects.</p>Formula:C21H16Cl2N4O2Color and Shape:SolidMolecular weight:427.28TG 100572
CAS:<p>TG 100572 is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2</p>Formula:C26H26ClN5O2Purity:98%Color and Shape:SolidMolecular weight:475.97LBW242
CAS:<p>LBW242: oral 3-mer Smac mimetic, IAP inhibitor, targets multiple myeloma, enhances TRAIL/chemo death in ovarian cancer, active on mutant FLT3 cells.</p>Formula:C27H42N4O2Purity:98%Color and Shape:SolidMolecular weight:454.65Syk-IN-1
CAS:<p>Syk-IN-11 is a selective Syk inhibitor.</p>Formula:C18H22N8OColor and Shape:SolidMolecular weight:366.42SB-633825
CAS:<p>SB-633825 can inhibit cancer cell growth and angiogenesis.</p>Formula:C28H25N3O3SPurity:98%Color and Shape:SolidMolecular weight:483.58OICR-0547
CAS:<p>OICR-0547 is an inactive derivative of OICR-9429 and is commonly used as a negative control for OICR-9429.</p>Formula:C28H29F3N4O4Purity:98%Color and Shape:SolidMolecular weight:542.55ALK2-IN-5
CAS:<p>ALK2-IN-5, a pyrazolopyrimidine compound, serves as an inhibitor of ALK2 and FGFR, targeting disorders linked with their activity, including cancer [1].</p>Formula:C24H32N8O2Color and Shape:SolidMolecular weight:464.56Depatuxizumab mafodotin
CAS:<p>Depatuxizumab mafodotin, an antibody-drug conjugate (ADC) targeting the epidermal growth factor receptor (EGFR), is utilized in cancer research [1].</p>Color and Shape:LiquidVEGFR-2-IN-20
CAS:<p>VEGFR-2-IN-20 (Compound 7) is a highly effective VEGFR inhibitor with significant potential for cancer research [1].</p>Formula:C20H20N4O3SColor and Shape:SolidMolecular weight:396.46PF-00337210
CAS:<p>PF-00337210, an oral VEGFR2 inhibitor, may hinder endothelial and tumor cell growth, reducing angiogenesis and potentially causing cancer cell death.</p>Formula:C26H27N3O5Color and Shape:SolidMolecular weight:461.51EGFR-IN-89
CAS:<p>EGFR-IN-89 (compound 13k) is a fourth-generation inhibitor selectively targeting EGFR mutations, exhibiting potent activity with an IC50 of 10.1 nM against</p>Formula:C26H31FN8O2SPurity:98%Color and Shape:SolidMolecular weight:538.64Gefitinib N-oxide
CAS:<p>Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib N-oxide is the N-oxide derivative of Gefitinib.</p>Formula:C22H24ClFN4O4Purity:98%Color and Shape:SolidMolecular weight:462.9Ibrutinib-MPEA
CAS:<p>Ibrutinib-MPEA is ibrutinib derivative. Ibrutinib is a covalent and irreversible BTK inhibitor that has been used to treat hematological malignancies.</p>Formula:C32H39N9O2Color and Shape:SolidMolecular weight:581.71BIIB-057
CAS:<p>BIIB-057 is a selective Syk inhibitor.</p>Formula:C19H23N9OPurity:98%Color and Shape:SolidMolecular weight:393.45Sitravatinib malate
CAS:<p>Sitravatinib malate is an orally bioavailable receptor inhibitor of tyrosine kinase (RTK) (IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5</p>Formula:C37H35F2N5O9SPurity:98%Color and Shape:SolidMolecular weight:763.76VEGFR-2-IN-27
CAS:<p>VEGFR-2-IN-27 (compound 7a) is a potent inhibitor of VEGFR-2 (IC50: 14.8 nM) and can be used in anticancer studies.</p>Formula:C25H21FN4O4Color and Shape:SolidMolecular weight:460.46CP-547632 hydrochloride
CAS:<p>CP-547632 hydrochloride: oral VEGFR-2/FGF inhibitor (IC50: 11/9 nM), well-tolerated, antitumor.</p>Formula:C20H25BrClF2N5O3SColor and Shape:SolidMolecular weight:568.86FLT3/ITD-IN-3
CAS:<p>FLT3/ITD-IN-3 (Compound 19) is a potent FLT3-ITD inhibitor with IC50 values: FLT3D835Y (0.3 nM), FLT3 (0.4 nM), inhibits AML cell proliferation.</p>Formula:C22H26ClN7O2Color and Shape:SolidMolecular weight:455.94WY-135
CAS:<p>WY-135 is a dual inhibitor of ALK and ROS1 (IC50 of 1.4 nM and 1.1 nM, respectively).</p>Formula:C28H34ClN9O3SPurity:98%Color and Shape:SolidMolecular weight:612.15FIIN-4
CAS:<p>FIIN-4 is a covalent inhibitor of FGFR and can be used in studies about metastatic breast cancer.</p>Formula:C35H38N8O4Purity:>99.99%Color and Shape:SolidMolecular weight:634.73EP009
CAS:<p>EP009, a novel, selective, and orally active inhibitor of JAK3, induces therapeutic response in T-cell malignancies.</p>Formula:C14H24O2Color and Shape:SolidMolecular weight:224.34AG1433
CAS:<p>AG1433: inhibits tyrosine kinases, PEP carboxylase, PDGFR-β, Flk-1, and angiogenesis.</p>Formula:C16H15ClN2O2Color and Shape:SolidMolecular weight:302.76EGFR-IN-51
CAS:<p>EGFR-IN-51 effectively inhibits EGFR and mutations with IC50s of 0.493-461.63 μM; it induces apoptosis in cancer cells.</p>Formula:C21H15N3O2SColor and Shape:SolidMolecular weight:373.43CHMFL-ABL/KIT-155
CAS:<p>CHMFL-ABL/KIT-155 is a highly potent and orally active type II ABL/c-KIT dual kinase inhibitor (IC50s: 46 nM/75 nM).</p>Formula:C33H38F3N5O3Purity:98%Color and Shape:SolidMolecular weight:609.68Tyk2-IN-7
CAS:<p>Tyk2-IN-7 is an inhibitor of TYK2 JH2, binds to the TYK2 JH2 domain (IC50: 0.00053 μM; Ki.app: 0.00007 μM).</p>Formula:C18H15D3N6O3SPurity:98%Color and Shape:SolidMolecular weight:401.46MS-1020
CAS:<p>MS-1020 inhibits JAK3/STAT3, blocks active JAK3, suppresses JAK3/STAT5 signaling, and targets STAT3 in certain cells.</p>Formula:C21H18N2O3Purity:98%Color and Shape:SolidMolecular weight:346.38Cenisertib
CAS:<p>Cenisertib is A potent ATP-competitive multi-kinase inhibitor, showing inhibitory effects on the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5, FLT3, as well</p>Formula:C24H30FN7OColor and Shape:SolidMolecular weight:451.541,2,3,4,5,6-Hexabromocyclohexane
CAS:<p>Inhibits JAK2 autophosphorylation; non-cytotoxic at 100μM; 1μM reduces activity by 50%, 50μM nearly abolishes it.</p>Formula:C6H6Br6Purity:98%Color and Shape:SolidMolecular weight:557.54MS 39
CAS:<p>MS 39, a selective EGFR depressant, degrades mutant receptors in lung cancer lines without affecting wild-type. Effective in vitro and in mice.</p>Formula:C55H71ClFN9O7SColor and Shape:SolidMolecular weight:1056.72PF-06651481-00
CAS:<p>PF-06651481-00 (Bosutinib Isomer I) is a Bosutinib analog and a Bcr-Abl inhibitor.</p>Formula:C26H29Cl2N5O3Purity:97.01%Color and Shape:SolidMolecular weight:530.45INCB16562
CAS:<p>INCB16562: oral JAK1/2 inhibitor, halts IL-6/STAT3 in myeloma cells, boosts drug efficacy, stunts myeloma in mice.</p>Formula:C19H11Cl2N5Color and Shape:SolidMolecular weight:380.23Jaspamycin
CAS:<p>Jaspamycin (7-CN-7-C-Ino) does not bind with purified human PKARIα.</p>Formula:C12H12N4O5Color and Shape:SolidMolecular weight:292.25FLT3-IN-12
CAS:<p>FLT3-IN-12: potent, selective oral FLT3 inhibitor; FLT3-WT IC50: 1.48 nM, FLT3-D835Y: 2.87 nM; >1000x selective over c-KIT; anti-AML, IC50: 0.75 nM MV4-11.</p>Formula:C21H23F3N6OColor and Shape:SolidMolecular weight:432.44JAK3-IN-9
CAS:<p>JAK3-IN-9, potent JAK3 inhibitor, IC50 of 1.7 nM, highly selective, low toxicity, orally bioavailable, shows anti-arthritis activity.</p>Formula:C17H23N5O4SColor and Shape:SolidMolecular weight:393.46ALK5-IN-29
CAS:<p>ALK5-IN-29: selective ALK inhibitor, IC50 ≤ 10 nM, curbs tumor growth, aids in cancer research.</p>Formula:C24H25FN8Color and Shape:SolidMolecular weight:444.51NVP-AAD777
CAS:<p>NVP-AAD777 is a specific VEGFR-2 inhibitor.</p>Formula:C22H14F6N4Purity:98%Color and Shape:SolidMolecular weight:448.36VEGFR-2/BRAF-IN-1
<p>VEGFR-2/BRAF-IN-1 inhibits VEGFR-2, BRAF V600E & BRAF WT with IC50 of 49, 63 and 5 nM, triggers apoptosis, and halts G1/S cell cycle.</p>Formula:C26H20Cl2F3N5O3S2Color and Shape:SolidMolecular weight:642.5XST-14
CAS:<p>XST-14 is a ULK1 inhibitor.XST-14 induces apoptosis and inhibits the growth of HCC cells.</p>Formula:C16H21NO4Purity:99.84% - 99.84%Color and Shape:SolidMolecular weight:291.34GZD856
CAS:<p>GZD856 is an orally bioavailable PDGFRα/β inhibitor (IC50s: 68.6 and 136.6 nM) with anti-lung cancer activities.</p>Formula:C29H27F3N6OPurity:98%Color and Shape:SolidMolecular weight:532.56KRN383
CAS:<p>KRN383 inhibits ITD cell growth at ≤2.9 nM, erases ITD tumors in mice at 80 mg/kg dose, and may suit various treatment plans.</p>Formula:C17H17N3O4Color and Shape:SolidMolecular weight:327.33
